Role of azoles in antifungal therapy

Clinical Infectious Diseases

Volumn 22, Issue SUPPL. 2, 1996, Pages

  Kauffman, Carol A ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE;

BLASTOMYCOSIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; CONFERENCE PAPER; DRUG EFFICACY; FUNGAL MENINGITIS; HISTOPLASMOSIS; HISTORY OF MEDICINE; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; MYCOSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; SPOROTRICHOSIS;

EID: 0030058469     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/22.supplement_2.s148     Document Type: Conference Paper

References (72)

1. Parker JD, Sarosi GA, Doto IL, Bailey RE, Tosh FE. Treatment of chronic pulmonary histoplasmosis: a National Communicable Disease Center cooperative mycoses study. N Engl J Med 1970;283:225-9.
2. Sarosi GA, Voth DW, Dahl BA, Doto IL, Tosh FE. Disseminated histoplasmosis: results of long-term follow-up. A Center for Disease Control cooperative mycoses study. Ann Intern Med 1971;75:511-6.
3. Reddy P, Gorelick DF, Brasher CA, Larsh H. Progressive disseminated histoplasmosis as seen in adults. Am J Med 1970;48:629-36.
4. Blastomycosis Cooperative Study of the Veterans Administration. Blastomycosis. I. A review of 198 collected cases in Veterans Administration hospitals. Am Rev Respir Dis 1964;89:659-72.
5. Busey JF. Blastomycosis. III. A comparative study of 2-hydroxystilbamidine and amphotericin B therapy. Am Rev Respir Dis 1972;105: 812-8.
6. Dismukes WE, Stamm AM, Graybill JR, et al. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med 1983;98:13-20.
7. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial. Ann Intern Med 1985;103:861-72.
8. Bradsher RW, Rice DC, Abernathy RS. Ketoconazole therapy for endemic blastomycosis. Ann Intern Med 1985;103:872-9.
9. Galgiani JN, Stevens DA, Graybill JR, Dismukes WE, Cloud GA. Ketoconazole therapy of progressive coccidioidomycosis: comparison of 400-and 800-mg doses and observations at higher doses. Am J Med 1988;84:603-10.
10. DeFelice R, Galgiani JN, Campbell SC, et al. Ketoconazole treatment of nonprimary coccidioidomycosis: evaluation of 60 patients during three years of study. Am J Med 1982;72:681-7.
11. Sangeorzan JA, Bradley SF, He X, et al. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994;97:339-46.
12. Bart-Delabesse E, Boiron P, Carlotti A, Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol 1993;31:2933-7.
13. Pfaller MA, Rhine-Chalberg J, Redding SW, et al. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 1994;32:59-64.
14. He X, Tiballi RN, Zarins LT, Bradley SF, Sangeorzan JA, Kauffman CA. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994;38:2495-7.
15. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
16. White A, Goetz MB. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review. Clin Infect Dis 1994;19: 687-92.
17. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326;83-9.
18. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:793-8.
19. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
20. Larsen RA, Leal MAE, Chan LS. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS: a randomized trial. Ann Intern Med 1990;113:183-7.
21. Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. Am J Med 1992;93:489-97.
22. Johnson PC, Khardori N, Najjar AF, Butt F, Mansell PWA, Sarosi GA. Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:152-8.
23. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990;69:361-74.
24. McKinsey DS, Gupta MR, Riddler SA, Driks MR, Smith DL, Kurtin PJ. Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989;111:655-9.
25. Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 1995;98:336-42.
26. Wheat J, Hafner R, Wulfsohn M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1993;118:610-6.
27. Smith D, Van de Velde V, Woestenborghs R, Gazzard BG. The pharmacokinetics of oral itraconazole in AIDS patients. J Pharm Pharmacol 1992;44:618-9.
28. Tucker RM, Denning DW, Arathoon EG, Rinaldi MG, Stevens DA. Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J Am Acad Dermatol 1990;23:593-601.
29. Graybill JR, Stevens DA, Galgiani JN, Dismukes WE, Cloud GA. Itraconazole treatment of coccidioidomycosis. Am J Med 1990;89:282-90.
30. Diaz M, Negroni R, Montero-Gei F, et al. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Clin Infect Dis 1992;14(suppl 1):S68-76.
31. Catanzaro A, Galgiani JN, Levine BE, et al. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. Am J Med 1995;98:249-56.
32. Galgiani JN. Coccidioidomycosis. West J Med 1993;159:153-71.
33. Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. Am J Med 1993;95:279-85.
34. Restrepo A, Robledo J, Gómez I, Tabares AM, Gutiérrez R. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol 1986;122:413-7.
35. Conti Diaz IA, Civila E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 1992;35:153-6.
36. Winn RE, Anderson J, Piper J, Aronson NE, Pluss J. Systemic sporotrichosis treated with itraconazole. Clin Infect Dis 1993;17:210-7.
37. Pluss JL, Opal SM. Pulmonary sporotrichosis: review of treatment and outcome. Medicine (Baltimore) 1986;65:143-53.
38. Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-44.
39. Viviani MA, Tortorano AM, Pagano A, et al. European experience with itraconazole in systemic mycoses. J Am Acad Dermatol 1990;23: 587-93.
40. Dupont B. Itraconazole therapy in aspergillosis: study in 49 patients. J Am Acad Dermatol 1990;23:607-14.
41. Blatchford NR. Treatment of oral candidosis with itraconazole: a review. J Am Acad Dermatol 1990;23:565-7.
42. Stein GE, Mummaw N. Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob Agents Chemother 1993;37:89-92.
43. van't Wout JW, Novakova I, Verhagen CAH, Fibbe WE, de Pauw BE, van der Meer JWM. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 1991;22:45-52.
44. Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989;149:2301-8.
45. Cauwenbergh G. Cryptococcal meningitis: the place of itraconazole. Mycoses 1993;36:221-8.
46. de Gans J, Portegies P, Tiessens G, et al. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992;6:185-90.
47. van der Horst C, Saag M, Cloud G, et al. Randomized double blind comparison of amphotericin B plus flucytosine to amphotericin B alone (step 1) followed by a comparison of fluconazole to itraconazole (step 2) in the treatment of cryptococcal meningitis in patients with AIDS (part 1) [abstract no I216]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
48. Saag M, van der Horst C, Cloud G, et al. Randomized double blind comparison of amphotericin B plus flucytosine to amphotericin B alone (step 1) followed by a comparison of fluconazole to itraconazole (step 2) in the treatment of cryptococcal meningitis in patients with AIDS (part 2) [abstract no I217]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
49. Saag MS, Cloud GC, Graybill JR, et al. Comparison of fluconazole vs. itraconazole as maintenance therapy of AIDS-associated cryptococcal meningitis [abstract no I218]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
50. Larsen RA, Bozzette SA, Jones BE, et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994;19:741-5.
51. Koletar SL, Russell JA, Fass RJ, Plouffe JF. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1990;34:2267-8.
52. de Wit S, Weerts D, Goossens H, Clumeck N. Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989;1:746-8.
53. Laine L, Dretler RH, Conteas CN, et al. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS: a randomized trial. Ann Intern Med 1992;117:655-60.
54. Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL. Use of fluconazole in the treatment of Candidal endophthalmitis. Clin Infect Dis 1995;20:657-64.
55. Voice RA, Bradley SF, Sangeorzan JA, Kauffman CA. Chronic candidal meningitis: an uncommon manifestation of candidiasis. Clin Infect Dis 1994;19:60-6.
56. Kauffman CA, Bradley SF, Ross SC, Weber DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991;91:137-41.
57. Anaissie E, Bodey GP, Kantarjian H, et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991;91:142-50.
58. Fisher JF, Newman CL, Sobel JD. Yeast in the urine: solutions for a budding problem. Clin Infect Dis 1995;20:183-9.
59. Voss A, Meis JFGM, Hoogkamp-Korstanje JAA. Fluconazole in the management of fungal urinary tract infections. Infection 1994;22:247-51.
60. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
61. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171: 1545-52.
62. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia: results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495-503.
63. Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex: randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med 1991;151:2458-64.
64. Powderly WG, Finkelstein DM, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-5.
65. Pappas PG, Bradsher RW, Chapman SW, et al. Treatment of blastomycosis with fluconazole: a pilot study. Clin Infect Dis 1995;20:267-71.
66. Kauffman CA, Pappas PG, McKinsey DS, et al. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis 1996;22:46-50.
67. Galgiani JN, Catanzaro A, Cloud GA, et al. Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 1993;119:28-35.
68. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-72.
69. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 1993;37:778-84.
70. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
71. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-9.
72. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994;38:1422-4.